Chapters Transcript Video Advancing Vascular Care, Together Back to Symposium But nonetheless, uh, I do wanna bring up our, our, our, my president, my supervisor, my president, and, uh, it's, it's wonderful actually working for Rema. Rema's a former president of UCC, had a lot of different positions here throughout the globe. She has global responsibilities for peripheral intervention, right, the artille side, the Venus side, um, certainly, but also the oncology side. That's the entire business is $2 billion business. She'll walk you through it and sort of talk about sort of where we're at and where we're going, most importantly. So with that being said, Rema, Albany, come on up at the station, Re. It's for you. You're welcome. All right. Alright, good evening, everyone. Welcome to the Advanced Peripheral Vascular summit. It's really a pleasure to be here hosting you tonight and tomorrow. So I'm Rima Alameddine. I work with Tim Hug, who doesn't know Tim Hug, but with all the peripheral intervention team across the globe. Yes, I have the, the honor and the pleasure to lead this business. And to work with so enthusiastic, passionate, and committed people that I have in my organization. Thanks for joining us and for the leadership that each one of you brings to advancing vascular care. We are really pleased to sponsor this event tonight and to hopefully be a valuable investment of your time. I want to thank again Doctor Erin Murphy, Doctor Eric Siminsky. The light is here. Perfect. Thank you again for. Being the course directors. But I wanna talk about why we're here today. So we have large meetings like this on a frequent basis and we're gonna have even more of those. And when we have this we say I say don't attend, let's say invest. The world is not attending this event, is investing in this event because this is truly an investment. Of time away from work away from our families, of time away from our commitments so I expect that this summit is an investment that pays off and that brings me to the objectives of this meeting. This is really designed around 3 goals. The first one, gain practical insights from experts advancing peripheral vascular care. You're here. Our second goal to explores to explore perspectives on innovative technologies shaping patient outcomes. And third, connect with peers across specialties. The real value of this time together comes from collective experience in this room today and tomorrow. And before we dive into the summit content, I really want to set some context on BT. So for Probably for who is still not aware we are part of VD because you might remember. Bart CR Bart the green logo BPV. Bart was acquired by BD in 2017 creating a new global leader in health tech, and the combined company was really uniquely positioned to improve both the treatment of disease for patients and the process of care for healthcare providers. Today, BD, a 125 plus year legacy company innovating in medical products, is one of the largest, as I said, med tech companies that really provides safe, effective, high quality solutions for healthcare providers to drive better patient outcomes across multiple areas of care. Across BD we focus on disease areas that represent significant and growing burdens or even opportunities for patients and healthcare systems. You'll see that our focus spans from areas like GLP1s and biologics, advanced patient monitoring, incontinence, pharmacy automation, molecular advanced tissue regeneration, to immunology, oncology research. It's important to say though that peripheral vascular disease is one of these priority areas. It really reflects the clinical complexity, the patient burden, and the long term commitments that are required to make meaningful progress. And our presence across these areas they really allow us to take a broad system level view of care while still maintaining deep focus where it matters most. Building on this focus in 25 BD announced a planned separation of our biosciences and diagnostic solutions uh businesses and the merger with Walters Bioscience and diagnostic Solutions, and this merger with Walters, it's really is expected to be completed by the end of this quarter March time frame. Pending regulatory and shareholder approvals and we'll really operate under under what their water's name. But why I'm telling you this? Why does this matter to you? Because as BD continues to evolve, our portfolio in peripheral vascular becomes even more focused. This allows us, so the, the portfolio across BD becomes more focused and the relevance of peripheral vascular is even higher. Because this allows us to sharpen our attention on areas where it can have meaningful impact. Like vascular care while continuing to invest with clarity and purpose. And this is gonna be the new BD. A focused global med tech leader with over almost $18 billion revenueualized revenue and as I said as BD evolves our focusing on areas where we can lead with clarity and purpose surfaces even more. Within BD PI peripheral intervention, which includes oncology, represents a significant business for the corporation, reflecting both the importance of this space and also the intention and the plans to remain deeply engaged in advancing care. With that context on BD. Its focus It's scale and its structure. I'd like to turn our attention to one of the areas especially relevant to this group, peripheral intervention, and specifically on the vascular side. A space defined by complex disease, high patient burden, and the need for thoughtful, durable solutions. It's also an area where BD has made long-term commitments to support clinicians and advancing care. And this is peripheral intervention. This is the business we are proud to work at. PI drives meaningful impact through both scale and innovation. Global leader in chronic disease care which provides experiences needed to support clinicians managing the most complex conditions. This is probably the page that I like most in this presentation because this reflects the uh this timeline reflects really several decades of innovation in peripheral intervention. Many of these technologies they have helped define or redefine standards of care at different moments in time. Looking back helps us understand how far the field has come and how quickly it continues to move. You probably cannot read. Maybe you can see some of the pictures and you can identify some of them. Certainly use several of these products. What sets us apart? Partnership quality and outcomes. The partnership that we have with you, we'll learn from you we'll listen to you not only to change the schedules and be flexible we'll listen to all your. Suggestions, your insights. Your dissatisfactions, and we take them into account in everything that we do. Your priorities they guide our choices. Quality it's the discipline that safeguards trust and delivers excellence quality in our solutions in our products in our service, in how we show up to you every single day at your practices. And the outcomes we build solutions that truly improve clinical and economic results. We are not gonna invest our time in Me Too technologies. We are not going to be just one more player in the space. That's not why we are here. We are here to be relevant, to make a difference, and we count on your insights, on your inputs to make this happen, otherwise it's a waste of time. Everything that we do begins and ends with the patient. Our mission to deliver superior solutions that address unmet needs and improve outcomes. And this is powered by our vision which I like to call. Our passion to transform vascular and cancer care by enabling earlier detection and less invasive treatment. And our purpose to reduce the burden of these diseases on patients, on patients, on clinicians, on caregivers, and systems worldwide. At the end of the day, everything that we have talked about that we'll talk about tonight and tomorrow. Comes back to this. It is about the patient. It's about the person behind every single procedure. It's about every decision and every outcome. And we don't give up. We don't. Not when diseases are complex, not when the path forward is unclear to us. And not when patients need us most. We don't give up. So that commitment is what brings us together at a forum like this to learn to share perspective. To listen, to challenge each other with purpose and to advance vascular care together. Thank you very much. I hope this investment pays off to all of you and to us thank you. Published Created by
Content on this site is intended for United States Healthcare Professionals Only
